Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
News
AllianceChicago to Offer Wellsheet’s Predictive Clinical Workflow Platform Integrated with athenahealth’s EHR
Wellsheet Integration with athenaOne to Empower Primary Care Clinicians in Community Health Centers
Venatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
– IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern
– IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms
Immunome Reports Third Quarter 2021 Financial Results
– IMM-BCP-01 Progressing Towards IND Filing –
Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing
Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large animal heart via local infusion at low vector doses
Strengthened company leadership with key appointments including Matthew Killeen, Ph.D., as CSO, and Elizabeth White, Ph.D., as CBO and SVP of Operations
Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results